Revvity earnings release, August 4, 2026

Revvity, Inc. (RVTY) · Form 8-K, Item 2.02 · Filed · SEC filing

August 4, 2026

Revvity Announces Financial Results for the Second Quarter of 2026

• Revenue of $730 million; pro forma revenue of $711 million;

4% pro forma revenue growth; 3% pro forma organic revenue growth

• GAAP EPS from continuing operations of

$0.48; adjusted EPS from continuing operations of $1.41; GAAP pro forma EPS from continuing operations of $0.52; pro forma adjusted EPS from continuing operations of $1.41

• Enters into definitive agreement to divest China Immunodiagnostics business

• Raises full year guidance

WALTHAM, Mass. --

Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended July 5, 2026.

The Company reported GAAP earnings per share from continuing operations of $0.48, as compared to $0.47 in the same period a year ago. Revenue for the quarter was $730 million, as compared to $720 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $89 million (which includes $16 million of tariff related refunds), as compared to $91 million for the same period a year ago. GAAP operating profit margin from continuing operations was 12.2% as a percentage of revenue, as compared to 12.6% in the same period a year ago.

Adjusted earnings per share from continuing operations for the quarter was $1.41, as compared to $1.18 in the same period a year ago. Adjusted operating income was $211 million, as compared to $192 million for the same period a year ago. Adjusted operating profit margin was 28.9% as a percentage of revenue, as compared to 26.6% in the same period a year ago.

Enters into Definitive Agreement to Divest China Immunodiagnostics Business

The Company recently entered into a definitive agreement to divest its Immunodiagnostics business in China (

“

China IDX”), which represented approximately 6% of the Company’s total revenue in fiscal year 2025. The transaction is expected to close by the end of 2027, subject to customary closing conditions and regulatory approvals.

The Company is providing second quarter 2026 financial results on a reported and pro forma basis; forward-looking guidance is provided on a pro forma basis only and excludes China IDX.

Pro forma earnings per share from continuing operations for the quarter was $0.52, as compared to $0.48 in the same period a year ago.

Pro forma revenue for the quarter was $711 million, as compared to $681 million in the same period a year ago.

Pro forma operating income was $94 million, as compared to $85 million in the same period a year ago. Pro forma operating profit margin was 13.2% as a percentage of pro forma revenue, as compared to 12.4% in the same period a year ago.

On a pro forma adjusted basis, earnings per share for the quarter was $1.41 (which includes approximately $0.11 from tariff related refunds), as compared to $1.15 in the same period a year ago. Pro forma adjusted operating income was $209 million

(which includes $16 million of tariff related refunds), as compared to $180 million for the same period a year ago. Pro forma adjusted operating profit margin was 29.3% as a percentage of pro forma revenue, as compared to 26.5% in the same period a year ago.

Adjustments for the Company’s non-GAAP financial measures have been noted in the attached reconciliations.

“Revvity delivered a strong second quarter, with results above our expectations and encouraging signs of increased demand across our customer base,” said Prahlad Singh, president and chief executive officer of Revvity. “As we enter the second half of the year, given the clear momentum in our end markets, we are utilizing a portion of recently received tariff refunds to increase investments across the business, capitalize on emerging opportunities, and support future growth.”

Financial Overview by Reporting Segment

Life Sciences

• Second quarter 2026 revenue was $359 million, as compared to $366 million in the same period a year ago. Pro forma revenue decreased 2% and pro forma organic revenue decreased 3% as compar ed to the same period a year ago.

• Second quarter 2026 adjusted operating income was $112 million, as compared to $115 million in the same period a year ago. Adjusted operating profit margin was 31.1% as a percentage of revenue, as compared to 31.6% in the same period a year ago.

Diagnostics

• Second quarter 2026 revenue was $371 million, as compared to $354 million in the same period a year ago. Pro forma revenue increased 12% and pro forma organic revenue increased 11% as compared to the same period a year ago.

• Second quarter 2026 adjusted operating income was $113 million, as compared to $89 million in the same period a year ago. Adjusted operating profit margin was 30.4% as a percentage of revenue, as compared to 25.2% in the same period a year ago.

Full Year 2026 Guidance

For the full year 2026, on a pro forma basis, the Company forecasts total revenue of $2.83-$2.86 billion, pro forma organic revenue growth of 4-5%, and pro forma adjusted earnings per share of $5.30-$5.40.

Guidance for the full year 2026 for pro forma organic revenue growth and pro forma adjusted EPS is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company’s results prepared in accordance with GAAP.

Webcast Information

The Company will discuss its second quarter 2026 results and its outlook for business trends during a webcast on August 4, 2026, at 7:30 a.m. Eastern Time. A live audio webcast and presentation will be available on the Investors section of the Company’s website, ir.revvity.com.

Use of Non-GAAP Financial Measures... (truncated)n-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.

Factors Affecting Future Performance

This press release contains

“ forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as

“ believes”,

“ intends”,

“ anticipates”,

“ plans”,

“ expects”,

“ estimates”,

“ projects”,

“ forecasts”,

Financial statements

Income Statement

Six Months Ended July 5, 2026 — UNAUDITED PRO FORMA CONDENSED CONSOLIDATED INCOME STATEMENTS (In thousands, except per share data)

Six Months Ended July 5, 2026 – HistoricalSix Months Ended July 5, 2026 – Disposition and Pro Forma AdjustmentsSix Months Ended July 5, 2026 – Pro FormaSix Months Ended June 29, 2025 – HistoricalSix Months Ended June 29, 2025 – Disposition and Pro Forma AdjustmentsSix Months Ended June 29, 2025 – Pro Forma
Revenue1,440,806-42,7851,398,0211,385,046-75,8011,309,245
Cost of revenue636,285-24,243612,042616,944-38,754578,190
Selling, general and administrative expenses532,458-26,943505,515498,2458,904507,149
Research and development expenses106,861-177106,684106,867106,867
Operating income from continuing operations165,2028,578173,780162,990-45,951117,039
Interest income-11,56328-11,535-18,42631-18,395
Interest expense47,70847,70845,90145,901
Change in fair value of investments9,4559,455-1,118-1,118
Other expense, net6,0794886,56715,601-1,30514,296
Income from continuing operations, before income taxes113,5238,062121,585121,032-44,67776,355
Provision for income taxes19,149-1,33517,81424,141-47723,664
Income from continuing operations94,3749,397103,77196,891-44,20052,691
Loss from discontinued operations-1,836-1,836-706-706
Net income92,5389,397101,93596,185-44,20051,985
Diluted earnings per share:Income from continuing operations0.840.930.820.44
Diluted earnings per share:Loss from discontinued operations-0.02-0.02-0.01-0.01
Diluted earnings per share:Net income0.820.910.810.43
Diluted earnings per share:Weighted average diluted shares of common stock outstanding111,746111,746118,882118,882
Diluted earnings per share:ABOVE PREPARED IN ACCORDANCE WITH GAAPABOVE PREPARED IN ACCORDANCE WITH GAAPABOVE PREPARED IN ACCORDANCE WITH GAAPABOVE PREPARED IN ACCORDANCE WITH GAAPABOVE PREPARED IN ACCORDANCE WITH GAAP

Income Statement

Twelve Months Ended December 28, 2025 — UNAUDITED PRO FORMA CONDENSED CONSOLIDATED INCOME STATEMENTS (In thousands, except per share data)

Twelve Months Ended December 28, 2025 – HistoricalTwelve Months Ended December 28, 2025 – Disposition and Pro Forma AdjustmentsTwelve Months Ended December 28, 2025 – Pro Forma
Revenue2,856,051-164,5522,691,499
Cost of revenue1,291,686-99,5581,192,128
Selling, general and administrative expenses991,890-26,688965,202
Research and development expenses215,840215,840
Operating income from continuing operations356,635-38,306318,329
Interest income-31,10376-31,027
Interest expense92,18592,185
Change in fair value of investments11,45611,456
Other expense, net15,820-2,76513,055
Income from continuing operations, before income taxes268,277-35,617232,660
Provision for income taxes28,3942,30730,701
Income from continuing operations239,883-37,924201,959
Income from discontinued operations1,3181,318
Net income241,201-37,924203,277
Diluted earnings per share:Income from continuing operations2.061.73
Diluted earnings per share:Income from discontinued operations0.010.01
Diluted earnings per share:Net income2.071.74
Diluted earnings per share:Weighted average diluted shares of common stock outstanding116,595116,595
Diluted earnings per share:ABOVE PREPARED IN ACCORDANCE WITH GAAPABOVE PREPARED IN ACCORDANCE WITH GAAPABOVE PREPARED IN ACCORDANCE WITH GAAP

Income Statement

Three Months Ended July 5, 2026 — CONDENSED CONSOLIDATED INCOME STATEMENTS (In thousands, except per share data)

Three Months Ended July 5, 2026 – As ReportedThree Months Ended July 5, 2026 – Pro FormaThree Months Ended June 29, 2025 – As ReportedThree Months Ended June 29, 2025 – Pro Forma
Revenue729,688711,109720,284680,547
Cost of revenue312,822302,876327,728306,814
Selling, general and administrative expenses278,576265,739248,526235,812
Research and development expenses48,97448,79853,27053,270
Operating income from continuing operations89,31693,69690,76084,651
Interest income-5,259-5,242-8,345-8,327
Interest expense22,99022,99022,93722,937
Change in fair value of investments5,2515,2511,9551,955
Other expense, net2,8034,0035,5634,868
Income from continuing operations, before income taxes63,53166,69468,65063,218
Provision for income taxes10,0508,21413,4286,754
Income from continuing operations53,48158,48055,22256,464
Loss from discontinued operations-1,661-1,661-1,274-1,274
Net income51,82056,81953,94855,190
Diluted earnings per share:Income from continuing operations0.480.520.470.48
Diluted earnings per share:Loss from discontinued operations-0.01-0.01-0.01-0.01
Diluted earnings per share:Net income0.470.510.460.47
Diluted earnings per share:Weighted average diluted shares of common stock outstanding111,629111,629117,538117,538
Diluted earnings per share:ABOVE PREPARED IN ACCORDANCE WITH GAAPABOVE PREPARED IN ACCORDANCE WITH GAAPABOVE PREPARED IN ACCORDANCE WITH GAAPABOVE PREPARED IN ACCORDANCE WITH GAAPABOVE PREPARED IN ACCORDANCE WITH GAAP

Income Statement

Three Months Ended July 5, 2026 — REVENUE AND OPERATING INCOME (LOSS) (In thousands, except percentages)

Three Months Ended July 5, 2026 – As ReportedThree Months Ended July 5, 2026 – Pro FormaThree Months Ended June 29, 2025 – As ReportedThree Months Ended – July 5, 2026Three Months Ended June 29, 2025 – As ReportedThree Months Ended – July 5, 2026Three Months Ended June 29, 2025 – Pro FormaThree Months Ended – June 29, 2025Three Months Ended June 29, 2025 – Pro FormaThree Months Ended – June 29, 2025
Revenue729,688711,109720,284680,547
Operating income from continuing operations89,31693,69690,76084,651
OP%12.213.212.612.4
Amortization of intangible assets84,87178,38385,28979,903
Purchase accounting adjustments1,8661,8662,1782,178
Acquisition and divestiture-related costs105391,2481,248
Transformation costs-736-736
Significant litigation matters and settlements79791,1241,124
Restructuring and other35,50835,19911,20311,203
Adjusted operating income211,009208,526191,802180,307
OP%28.929.326.626.5
Segment revenue:Life Sciences358,699365,898
Segment revenue:Diagnostics370,989354,386
Segment revenue:Segment revenue729,688720,284
Segment operating income:Life Sciences111,534115,469
Segment operating income:%31.131.6
Segment operating income:Diagnostics112,86689,422
Segment operating income:%30.425.2
Segment operating income:Segment operating income224,400204,891
Segment operating income:Corporate-13,391-13,089
Segment operating income:Adjusted operating income211,009191,802
Segment operating income:Amortization of intangible assets-84,871-85,289
Segment operating income:Purchase accounting adjustments-1,866-2,178
Segment operating income:Acquisition and divestiture-related costs-105-1,248
Segment operating income:Transformation costs736
Segment operating income:Significant litigation matters and settlements-79-1,124
Segment operating income:Restructuring and other-35,508-11,203
Segment operating income:Reported operating income from continuing operations89,31690,760

Income Statement

Six Months Ended July 5, 2026 — REVENUE AND OPERATING INCOME (LOSS) (In thousands, except percentages)

Six Months Ended July 5, 2026 – As ReportedSix Months Ended July 5, 2026 – Pro FormaSix Months Ended June 29, 2025 – As ReportedSix Months Ended – July 5, 2026Six Months Ended June 29, 2025 – As ReportedSix Months Ended – July 5, 2026Six Months Ended June 29, 2025 – Pro FormaSix Months Ended – June 29, 2025Six Months Ended June 29, 2025 – Pro FormaSix Months Ended – June 29, 2025
Revenue1,440,8061,398,0211,385,0461,309,245
Operating income from continuing operations165,202173,780162,990117,039
OP%11.512.411.88.9
Amortization of intangible assets169,952157,092167,989157,246
Purchase accounting adjustments2,0072,0072,0012,001
Acquisition and divestiture-related costs3873243,7893,789
Disposition of businesses and assets, net-5,074-5,074
Transformation costs5858
Loss from probable dispositions34,243
Significant litigation matters and settlements14814811,71011,710
Significant environmental matters-1,208-1,208

Balance Sheet

Disposition and Pro Forma Adjustments — AS OF JULY 5, 2026 (in thousands)

HistoricalDisposition and Pro Forma AdjustmentsPro Forma
Cash and cash equivalents1,022,9438,1661,031,109
Accounts receivable, net709,175-86,671622,504
Inventories, net378,502-7,142371,360
Other current assets187,10156,522243,623
Total current assets2,297,721-29,1252,268,596
Property, plant and equipment, net456,251-14,173442,078
Operating lease right-of-use assets, net150,945-4,232146,713
Intangible assets, net2,224,001-127,6752,096,326
Goodwill6,607,802-35,0006,572,802
Other assets, net309,11444,794353,908
Total assets12,045,834-165,41111,880,423
Current liabilities:Current portion of long-term debt572,156$—572,156
Current liabilities:Accounts payable165,740-3,679162,061
Current liabilities:Accrued expenses and other current liabilities538,4613,741542,202
Current liabilities:Total current liabilities1,276,357621,276,419
Current liabilities:Long-term debt2,633,094$—2,633,094
Current liabilities:Long-term liabilities771,359-33,490737,869
Current liabilities:Operating lease liabilities136,266-2,915133,351
Current liabilities:Total liabilities4,817,076-36,3434,780,733
Current liabilities:Total stockholders' equity7,228,758-129,0687,099,690
Current liabilities:Total liabilities and stockholders' equity12,045,834-165,41111,880,423
Current liabilities:PREPARED IN ACCORDANCE WITH GAAPPREPARED IN ACCORDANCE WITH GAAPPREPARED IN ACCORDANCE WITH GAAPPREPARED IN ACCORDANCE WITH GAAP

Balance Sheet

July 5, 2026 — CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands)

July 5, 2026December 28, 2025
Cash and cash equivalents1,022,943919,860
Accounts receivable, net709,175744,671
Inventories, net378,502379,497
Other current assets187,101195,719
Total current assets2,297,7212,239,747
Property, plant and equipment, net456,251479,249
Operating lease right-of-use assets, net150,945165,439
Intangible assets, net2,224,0012,347,003
Goodwill6,607,8026,613,493
Other assets, net309,114323,480
Total assets12,045,83412,168,411
Current liabilities:Current portion of long-term debt572,156588,828
Current liabilities:Accounts payable165,740185,464
Current liabilities:Accrued expenses and other current liabilities538,461556,954
Current liabilities:Total current liabilities1,276,3571,331,246
Current liabilities:Long-term debt2,633,0942,631,236
Current liabilities:Long-term liabilities771,359807,461
Current liabilities:Operating lease liabilities136,266148,108
Current liabilities:Total liabilities4,817,0764,918,051
Current liabilities:Total stockholders' equity7,228,7587,250,360
Current liabilities:Total liabilities and stockholders' equity12,045,83412,168,411
Current liabilities:PREPARED IN ACCORDANCE WITH GAAPPREPARED IN ACCORDANCE WITH GAAPPREPARED IN ACCORDANCE WITH GAAP

Cash Flow

Three Months Ended — CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands)

Three Months Ended – July 5, 2026Three Months Ended – June 29, 2025Six Months Ended – July 5, 2026Six Months Ended – June 29, 2025
Net income51,82053,94892,53896,185
Loss from discontinued operations, net of income taxes1,6611,2741,836706
Income from continuing operations53,48155,22294,37496,891
Adjustments to reconcile income from continuing operations to net cash provided by continuing operations:Stock-based compensation10,73110,13319,44617,864
Adjustments to reconcile income from continuing operations to net cash provided by continuing operations:Restructuring and other35,50811,20346,18314,442

Cash Flow

Three Months Ended — CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands)

Three Months Ended – July 5, 2026Three Months Ended – June 29, 2025Six Months Ended – July 5, 2026Six Months Ended – June 29, 2025
Payments of debt financing costs-72-2,474
Payments on other credit facilities-53-103
Payments for acquisition-related contingent consideration-350-161-350-1,978
Proceeds from issuance of common stock under stock plans9966,4372,632
Purchases of common stock-15,992-293,907-102,488-447,501
Dividends paid-7,814-8,282-15,654-16,715
Net cash used in financing activities-23,160-302,475-112,055-466,139
Effect of exchange rate changes on cash, cash equivalents, and restricted cash-2,56331,953-10,19048,075
Net increase (decrease) in cash, cash equivalents, and restricted cash162,715-145,697103,151-171,462
Cash, cash equivalents, and restricted cash at beginning of period861,4661,138,687921,0301,164,452
Cash, cash equivalents, and restricted cash at end of period1,024,181992,9901,024,181992,990
Reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total shown in the consolidated statements of cash flows:Cash and cash equivalents1,022,943991,8491,022,943991,849
Reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total shown in the consolidated statements of cash flows:Restricted cash included in other current assets7131,1417131,141
Reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total shown in the consolidated statements of cash flows:Restricted cash included in other assets525525
Reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total shown in the consolidated statements of cash flows:Total cash, cash equivalents and restricted cash1,024,181992,9901,024,181992,990
Reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total shown in the consolidated statements of cash flows:PREPARED IN ACCORDANCE WITH GAAPPREPARED IN ACCORDANCE WITH GAAP
Full release

“ will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments, including as the result of recently implemented and recently threatened tariff increases; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and divestitures, license technologies, or to successfully integrate acquired businesses or licensed technologies into our existing businesses or to make them profitable; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (8) disruptions in the supply of raw materials and supplies; (9) our ability to retain key personnel; (10) significant disruption in our information technology systems, or cybercrime; (11) uncertainties related to the development and use of AI in our product offerings and internal operations; (12) our ability to realize the full value of our intangible assets; (13) our failure to adequately protect our intellectual property; (14) the loss of any of our licenses or licensed rights; (15) the manufacture and sale of products exposing us to product liability claims; (16) our failure to maintain compliance with applicable government regulations; (17) our failure to comply with data privacy and information security laws and regulations; (18) regulatory changes; (19) our failure to comply with healthcare industry regulations; (20) economic, political and other risks associated with foreign operations; (21) our ability to obtain future financing; (22) restrictions in our credit agreements; (23) significant fluctuations in our stock price; (24) reduction or elimination of dividends on our common stock; and (25) other factors which we describe under the caption

“

Risk Factors” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.